Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06617936
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-25
Brief Title:
Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer
Sponsor:
Organization:
None